Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
6.65
-0.05 (-0.75%)
Aug 14, 2025, 1:44 PM - Market open
Imunon Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
16.77M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IMNN News
- 8 days ago - IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call - GlobeNewsWire
- 9 days ago - Imunon, Inc. (IMNN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 15 days ago - IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - GlobeNewsWire
- 16 days ago - IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025 - GlobeNewsWire
- 17 days ago - IMUNON Announces Stock Dividend Boosting Shareholder Value - GlobeNewsWire
- 22 days ago - IMUNON Announces Reverse Stock Split - GlobeNewsWire
- 4 weeks ago - IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan - GlobeNewsWire